Sclerostin - a potential new marker of exercise influence on vascular calcification and mineral and bone disorder in hemodialysed adults

Agnieszka Turon-Skrzypinska, Grazyna Dutkiewicz, Malgorzata Marchelek-Myśliwiec, Aleksandra Ryl, Artur Uzdzicki, Tomasz Przybylski, Iwona Rotter

DOI: http://dx.doi.org/10.12775/JEHS.2019.09.12.007

Abstract


Chronic Kidney Disease (CKD) is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health. Amongst CKD complications the most fatal is cardiovascular disease, which together with Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) share a possible origin in Wnt signaling pathway disturbances. Sclerostin, a potent Wnt signaling inhibitor may possibly be used as a potential new marker of exercise influence on vascular calcification and mineral and bone disorder in hemodialysed adults.

Keywords


sclerostin; Chronic Kidney Disease Mineral and Bone Disorder; exercise

Full Text:

PDF

References


Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplements, 2013; 3: 1–150.

Coresh J, Selvin E, Stevens LA, et al. Prevalence of Chronic Kidney Disease in the United States. JAMA. 2007;298(17):2038–2047. doi:https://doi.org/10.1001/jama.298.17.2038

Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-2219

A Meguid El Nahas, Aminu K Bello, Chronic kidney disease: the global challenge, The Lancet, Volume 365, Issue 9456, 2005, Pages 331-340, ISSN 0140-6736.

Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-Americans and white men: 16-year MRFIT findings. JAMA 1997; 277: 1293–98

Sharon M. Moe, Tilman Drüeke, Norbert Lameire, Garabed Eknoyan, Chronic Kidney Disease–Mineral-Bone Disorder: A New Paradigm, Advances in Chronic Kidney Disease, Volume 14, Issue 1, 2007, Pages 3-12, ISSN 1548-5595.

Mehrotra R, Chiu Y, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar Outcomes With Hemodialysis and Peritoneal Dialysis in Patients With End-Stage Renal Disease. Arch Intern Med. 2011;171(2):110–118.

Alfred-Demas, R.; Moore, B.; Trim, A.; Sandy-Robinson, A.; Wasunna, A.Cardiovascular Parameters in Chronic Haemodialysis Patients in Tobago. West Indian Medical Journal . 2018, Vol. 67 Issue 2, p157-159. 3p.

Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002; 13: 1918–1927.

Glenn M. Chertow, Paolo Raggi, Scott Chasan-Taber, Juergen Bommer, Herwig Holzer, Steven K. Burke, Determinants of progressive vascular calcification in haemodialysis patients, Nephrology Dialysis Transplantation, Volume 19, Issue 6, June 2004, Pages 1489–1496.

Levey AS, Coresh J, Balk E, et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Ann Intern Med. 2003;139:137–147.

Early Control of PTH and FGF23 in Normophosphatemic CKD Patients: A New Target in CKD-MBD Therapy? Rodrigo B. Oliveira, Ana L.E. Cancela, Fabiana G. Graciolli, Luciene M. Dos Reis, Sérgio A. Draibe, Lilian Cuppari, Aluizio B. Carvalho, Vanda Jorgetti, Maria E. Canziani, Rosa M.A. Moysés CJASN Feb 2010, 5 (2) 286-291; DOI: 10.2215/CJN.05420709.

Mario Cozzolino, Pablo Ureña-Torres, Marc G. Vervloet, Vincent Brandenburg, Jordi Bover, David Goldsmith, Tobias E. Larsson, Ziad A. Massy, Sandro Mazzaferro, on behalf of the CKD-MBD Working Group of ERA-EDTA, Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?, Nephrology Dialysis Transplantation, Volume 29, Issue 10, October 2014, Pages 1815–1820.

Thambiah, S., Roplekar, R., Manghat, P., Fogelman, I., Fraser, W. D., Goldsmith, D., & Hampson, G. (2012). Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcified tissue international, 90(6), 473-480.

Takuo Kubota, Toshimi Michigami, Keiichi Ozono. Wnt signaling in bone metabolism. J Bone Miner Metab (2009) 27:265–271.

Thambiah, S., Roplekar, R., Manghat, P., Fogelman, I., Fraser, W. D., Goldsmith, D., & Hampson, G. (2012). Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcified tissue international, 90(6), 473-480.

Janik, M., Stuss, M., Michalska-Kasiczak, M., Jegier, A., & Sewerynek, E. (2018). Effects of physical activity on sclerostin concentrations. Endokrynologia Polska, 69(2), 142-149.

Chung Y.C., Yeh M.L., Liu Y.M.: Effects of intradialytic exercise on the physical function, depression and quality of life for haemodialysis patients: a systematic review and meta-analysis of randomised controlled trials. J Clin Nurs 2017; 26 (13-14): 1801-1813. Dostępny w: doi: 10.1111/jocn.13514.

Kong C.H., Tattersall J.E., Greenwood R.N., Farrington K.: The effect of exercise during haemodialysis on solute removal. Nephrol Dial Transplant 1999; 14 (12): 2927–2931.

Emilia Mierzwińska, Tomasz Hryszko, Emilia Szablak-Uliszewska, Beata Naumnik. Sklerostyna i przewlekła choroba nerek. Postepy Hig Med Dosw 2017; 71 : 1098-1106.

Chantrel, F., Deloumeaux, J., Lange, C., & Lassalle, M. (2013). Survival and mortality in ESRD patients. Nephrologie & therapeutique, 9, S127-37.

Boyde, A. (2003). The real response of bone to exercise. Journal of anatomy, 203(2), 173-189.

Association of SOST gene polymorphisms with peak bone mineral density in Chinese nuclear families with male-offspring. Qi L, et al. Acta Biochim Biophys Sin (Shanghai), 2019 Mar 1. PMID 30883645.

Guerriere, K. I., Hughes, J. M., Gaffney‐Stomberg, E., Staab, J. S., & Matheny Jr, R. W. (2018). Circulating sclerostin is not suppressed following a single bout of exercise in young men. Physiological reports, 6(10), e13695.

Clarke B.L., Drake M.T.: Clinical utility of serum sclerostin measurements. Bonekey Rep 2013; 2: 361.

Kouvelioti R, Kurgan N, Falk B, Ward WE, Josse AR, Klentrou P. Response of Sclerostin and Bone Turnover Markers to High Intensity Interval Exercise in Young Women: Does Impact Matter?. Biomed Res Int. 2018;2018:4864952. Published 2018 Nov 1. doi:10.1155/2018/4864952.

Lombardi G., Lanteri P., Colombini A., Mariotti M., Banfi G.: Sclerostin concentrations in athletes: role of load and gender. J Biol Regul Homeost Agents 2012; 26 (1): 157–163.

Guerriere, K. I., Hughes, J. M., Gaffney-Stomberg, E., Staab, J. S., & Matheny, R. W. (2018). Circulating sclerostin is not suppressed following a single bout of exercise in young men. Physiological Reports, 6(10), e13695.

Gombos GC, Bajsz V, Pék E, et al. Direct effects of physical training on markers of bone metabolism and serum sclerostin concentrations in older adults with low bone mass. BMC Musculoskelet Disord. 2016;17:254. Published 2016 Jun 8. doi:10.1186/s12891-016-1109-5.

Falk B, Haddad F, Klentrou P, et al. Differential sclerostin and parathyroid hormone response to exercise in boys and men. Osteoporos Int. 2016;27(3):1245–1249. doi:10.1007/s00198-015-3310-z.

Sharma-Ghimire, P., Chen, Z., Sherk, V., Bemben, M., & Bemben, D. (2019). Sclerostin and parathyroid hormone responses to acute whole-body vibration and resistance exercise in young women. Journal of bone and mineral metabolism, 37(2), 358-367.

Ardawi, M. S. M., Rouzi, A. A., & Qari, M. H. (2012). Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. The Journal of Clinical Endocrinology & Metabolism, 97(10), 3691-3699.

Hinton PS, Nigh P, Thyfault J. Serum sclerostin decreases following 12 months of resistance- or jump-training in men with low bone mass. Bone. 2017;96:85–90. doi:10.1016/j.bone.2016.10.011.

I. Bergstrom, P. Parini, S.A. Gustafsson, G. Andersson, J. Brinck, Physical training increases osteoprotegerin in postmenopausal women. J. Bone Miner. Metab. 30(2), 202–207 (2012)

Kerschan-Schindl K, Thalmann MM, Weiss E, et al. Changes in Serum Levels of Myokines and Wnt-Antagonists after an Ultramarathon Race. PLoS One. 2015;10(7):e0132478. Published 2015 Jul 6. doi:10.1371/journal.pone.0132478

Liao, H. W., Huang, T. H., Chang, Y. H., Liou, H. H., Chou, Y. H., Sue, Y. M., ... & Tsai, K. J. (2019). Exercise Alleviates Osteoporosis in Rats with Mild Chronic Kidney Disease by Decreasing Sclerostin Production. International journal of molecular sciences, 20(8), 2044.

Cejka D., Marculescu R., Kozakowski N., Plischke M., Reiter T.,Gessl A., Haas M.: Renal elimination of sclerostin increases with declining kidney function. J. Clin. Endocrinol. Metab., 2014; 99: 248-255.

Desjardins L., Liabeuf S., Oliveira R.B., Louvet L., Kamel S., Lemke H.D., Vanholder R., Choukroun G., Massy Z.A., European Uremic Toxin (EUTox) Work Group: Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol. Ther., 2014; 10: 463-470.

Morena M, Jaussent I, Dupuy AM, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant 2015; 30: 1345–1356.

Lv W., Guan L., Zhang Y., Yu S., Cao B., Ji Y.: Sclerostin as new key factor in vascular calcification in chronic kidney disease stages 3 and 4. Int. Urol. Nephrol., 2016; 48: 2043-2050.

Qureshi A.R., Olauson H., Witasp A., Haarhaus M., Brandenburg, V., Wernerson A., Lindholm B., Söderberg M., Wennberg L., Nordfors L., Ripsweden J., Barany P., Stenvinkel P.: Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int., 2015; 88: 1356-1364.

Li, M., Zhou, H., Yang, M., & Xing, C. (2019). Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study. International urology and nephrology, 51(2), 311-323.

Byon CH, Chen Y. Molecular mechanisms of vascular calcification in chronic kidney disease: the link between bone and the vasculature. Curr Osteoporos Rep. 2015;13:206–215.

Evenepoel P, Goffin E, Meijers B, Kanaan N, Bammens B, Coche E, Claes K, Jadoul M (2015) Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients. J Clin Endocrinol Metab 100(12):4669–4676.

Nguyen-Yamamoto L, Tanaka KI, St-Arnaud R, Goltzman D. Vitamin D-regulated osteocytic sclerostin and BMP2 modulate uremic extraskeletal calcification. JCI Insight. 2019;4(13):e126467. Published 2019 Jul 11. doi:10.1172/jci.insight.126467.

Mödder UI, Hoey KA, Amin S, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men, J Bone Miner Res , 2011, vol. 26 (pg. 373-379).

Daniel Cejka, Agnes Jäger-Lansky, Heidi Kieweg, Michael Weber, Christian Bieglmayer, Dominik G. Haider, Danielle Diarra, Janina M. Patsch, Franz Kainberger, Barbara Bohle, Martin Haas, Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients, Nephrology Dialysis Transplantation, Volume 27, Issue 1, January 2012, Pages 226–230.

Boltenstål, H., Qureshi, A. R., Behets, G. J., Lindholm, B., Stenvinkel, P., D’Haese, P. C., & Haarhaus, M. (2019). Association of Serum Sclerostin with Bone Sclerostin in Chronic Kidney Disease is Lost in Glucocorticoid Treated Patients. Calcified tissue international, 104(2), 214-223.

Cejka, D., Herberth, J., Branscum, A.J. et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011; 6: 877–882.

Ji, Y. Q., Guan, L. N., Yu, S. X., Yin, P. Y., Shen, X. Q., Sun, Z. W., ... & Ren, C. (2018). Serum sclerostin as a potential novel biomarker for heart valve calcification in patients with chronic kidney disease. European review for medical and pharmacological sciences, 22(24), 8822-8829.


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM




Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

https://pbn.nauka.gov.pl/sedno-webapp/search?search&searchCategory=WORK&filter.inJournal=36616

POL-index 2011 - 2014

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-32a319c5-a850-4f44-ba70-1418a6087655

BASE 2011 - 2014

https://www.base-search.net/Search/Results?lookfor=Journal+of+Health+Sciences+%28Radom%29&type=all&oaboost=1&ling=1&name=&thes=&refid=dcrespl&newsearch=1

http://elibrary.ru/contents.asp?titleid=37467

http://journal.rsw.edu.pl/index.php/JHS/issue/archive

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska, EuroPub database, NLM Catalog Result - NCBI, BASE, Russian Sciences Index, Arianta.

https://zdb-katalog.de/title.xhtml?idn=1080187162

https://europub.co.uk/journals/22625

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

https://www.ncbi.nlm.nih.gov/nlmcatalog/101679844

Find a library that holds this journal: http://worldcat.org/issn/23918306

 

PBN Poland

https://pbn.nauka.gov.pl/sedno-webapp/journals/49068

POL-index

https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-c39c8169-88d2-45db-9e7f-d948ce9981c4

BASE

https://www.base-search.net/Search/Results?join=AND&bool0[]=AND&lookfor0[]=2391-8306&type0[]=all&page=11&l=pl&oaboost=1&refid=dcpagepl

Redaction, Publisher and Editorial Office

Publisher and Editorial Office
Department of Physical Culture,
Faculty of Earth Sciences and Spatial Management,
Nicolaus Copernicus University in Toruń, Poland
Address: Str. Lwowska 1, 87-100 Toruń, Poland

  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at https://dbh.nsd.uib.no/publiseringskanaler/erihplus/periodical/info?id=485984

Indexed in Index Copernicus Journals Master List.

http://journals.indexcopernicus.com/Journal+of+Education+Health+and+Sport,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

RG Journal Impact: 0.18 *

*This value is calculated using ResearchGate data and is based on average citation counts from work published in this journal. The data used in the calculation may not be exhaustive.

RG Journal impact history

2020Available summer 2021
2018 / 20190.18
20170.07
20160.03

RG Journal impact over time

RG Journal impact
0.180.160.140.120.100.080.060.040.02201620172018
  

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (https://pbn.nauka.gov.pl/journals/36616)

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ) http://elibrary.ru/contents.asp?titleid=37467

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski

(http://www1.bg.us.edu.pl/bazy/czasopisma/czasop_full.asp?id=3595)

Partnerzy platformy czasopism